Health ❯ Healthcare ❯ Clinical Trials ❯ Phase 3 Trials

Weight Loss Medications

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Full results are slated for presentation at the American Diabetes Association meeting in June.

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial